Asahi Kasei Bioprocess and Axolabs announce strategic partnership to accelerate oligonucleotide therapeutics development
Düsseldorf, Tokyo and New York – April 11, 2024 – Asahi Kasei Bioprocess (AKB), part of the Asahi Kasei Group, and Axolabs have announced a strategic partnership in the burgeoning field of oligonucleotide therapeutics. The partners will collaborate…